Agenus Receives Fast Track Designation for Balstilimab & Zalifrelimab in Advanced Cervical Cancer

Stock Information for Agenus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Agenus Inc.

Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
Agenus Announces Reverse Stock Split of Common Stock
Agenus Reports Fourth Quarter and Full Year 2023 Results
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.